People · Operator
Named in public records as an officer, director or promoter · active 2012–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kite Pharma, Inc. | — | Biotechnology | Series C | $79.1M | $2.0B | 2012 |
Roy B. Doumani at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Roy B. Doumani on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joshua A. Kazam | 1 | 10 |
| Arie S. Belldegrun | 1 | 5 |
| Jonathan M Peacock | 1 | 4 |
| Aya Jakobovits | 1 | 2 |
| Steven B. Ruchefsky | 1 | 2 |
| Marc R. Better | 1 | 1 |
| Farah B. Champsi | 1 | 1 |
| Ran B. Nussbaum | 1 | 1 |
| Rizwana R. Sproule | 1 | 1 |
| Keith M. Nolop | 1 | 1 |
| David A. Bonderman | 1 | 1 |
| Gloria S. Lee | 1 | 1 |
| Margo R. Roberts | 1 | 1 |
| Cynthia M. Butitta | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.